Ace Therapeutics, a preclinical contract research organization specializing in analgesic drug research, today announced the launch of its comprehensive preclinical analgesic drug development services featuring a full-spectrum pain research platform. The platform integrates validated in vivo pain models, in vitro assays, and a complete suite of research capabilities to support pharmaceutical and biotechnology clients worldwide in advancing pain therapeutics from target discovery to safety assessment.
The company's end-to-end solutions cover every stage of analgesic drug development, including early target identification, mechanism verification, pharmacological validation, and safety profiling. According to Ace Therapeutics, the platform is built on scientific rigor and regulatory-compliant methodologies, combining in vitro and in vivo research to study various physiological pain mechanisms and evaluate compound efficacy.
A core strength of the offering is its extensive portfolio of standardized and customized in vivo pain models for drug testing, which span nearly all mainstream pain classifications. These validated animal models include migraine models established via trigeminal ganglion electrical stimulation and nitroglycerin induction, as well as multiple neuropathic pain models such as spinal nerve ligation, chronic constriction injury, and diabetic neuropathic pain models.
To complement its in vivo systems, Ace Therapeutics has developed systematic preclinical pain assessment services, including mechanical pain, thermal pain, chemical pain, cold pain, and electrical stimulation pain assessments using well-established testing methods like the Von Frey Filament Test, Hot Plate Test, and Formalin Test. Additionally, in vitro neuropathic pain model development services leverage dorsal root ganglion (DRG) cells, iPSC-derived sensory neurons, and various co-culture systems to explore pain-related cellular mechanisms, enhancing the translational value of preclinical research.
Beyond model construction and efficacy testing, Ace Therapeutics' preclinical analgesic drug development services extend to target-based and modality-based drug discovery. These services support research targeting G-protein coupled receptors, cytokine networks, and various ion channels, delivering professional solutions for small-molecule analgesics, biologics including antibodies, recombinant proteins, peptides, cell therapies, and gene therapy candidates. The company also offers mechanism-driven research covering peripheral inflammatory pathways, central regulatory pathways, neuronal signaling pathways, and neuro-immune interaction pathways.
The full-service pipeline also includes target validation, in vitro screening, in vivo pharmacology research, pharmacokinetics analysis, safety pharmacology, preclinical formulation development, and biomarker discovery. Professional PK/PD modeling, toxicity assessment, and formulation optimization help clients reduce research risks, determine optimal dosages, and accelerate candidate selection for analgesic drugs. For special research needs, Ace Therapeutics can also design customized pain models and testing assays according to unique drug mechanisms and research objectives.
